Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 2/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31667236 | 0.93 | NPC1 (0.37) | NPC1POLBKDM4EALOX15SIGMAR1 | |
| SCHEMBL31667152 | 0.93 | NPC1 (0.46) | NPC1POLBSIGMAR1MIFTNIK | |
| SCHEMBL32686812 | 0.89 | MIF (0.41) | NPC1POLBMIFTNIKMEN1 | |
| SCHEMBL32686809 | 0.89 | CYP1A2 (0.33) | NPC1KDM4EMIFTNIKCYP1A2 | |
| SCHEMBL32686773 | 0.87 | NPC1 (0.39) | NPC1POLBSIGMAR1MIFTNIK | |
| SCHEMBL32686876 | 0.87 | TNIK (0.36) | NPC1POLBMIFTNIKMEN1 | |
| SCHEMBL32686867 | 0.87 | MEN1 (0.32) | NPC1MIFTNIKMEN1KMT2A | |
| SCHEMBL32686786 | 0.86 | SMN1; SMN2 (0.35) | NPC1POLBKDM4EMIFTNIK | |
| SCHEMBL31667652 | 0.86 | NPC1 (0.46) | NPC1SIGMAR1MIFTNIKKMT2A | |
| SCHEMBL32686769 | 0.85 | TNIK (0.37) | POLBMIFTNIKTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | NPC1 200/4885POLB 1690/4885KDM4E 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.